{"entity":{"id":"nct02671955","kind":"trial","name":"A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer","aka":[],"tldr":"A phase 1 trial of CI-8993 run by Janssen Research & Development, LLC, terminated.","summary":"A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer is a phase 1 interventional study registered as NCT02671955 by Janssen Research & Development, LLC, with 12 participants enrolled, started 2016-01. Conditions recorded: Advanced Cancer. Interventions recorded: JNJ-61610588.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT02671955","url":"https://clinicaltrials.gov/study/NCT02671955"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ci-8993"],"companies":["immunext","curis","johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02671955","phase":"1","setting":"An Open-label, First-in-Human, Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-61610588, a Fully Human IgG1 Kappa Anti-VISTA (V-domain Ig Suppressor of T-cell Activation) Monoclonal Antibody, in Subjects With Advanced Cancer","sponsor":"Janssen Research & Development, LLC","enrolled":12,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02671955/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"ci-8993","kind":"drug","name":"CI-8993","route":"/drugs/ci-8993/"}],"company":[{"id":"curis","kind":"company","name":"Curis","route":"/companies/curis/"},{"id":"immunext","kind":"company","name":"ImmuNext","route":"/companies/immunext/"},{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}